Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
- (-) Nuclear Science and Technology (2)
- Advanced Manufacturing (1)
- Biological Systems (1)
- Biology and Environment (41)
- Clean Energy (116)
- Climate and Environmental Systems (1)
- Computational Biology (2)
- Computational Engineering (2)
- Computer Science (8)
- Electricity and Smart Grid (3)
- Functional Materials for Energy (1)
- Fusion and Fission (6)
- Isotopes (6)
- Materials (53)
- Materials for Computing (11)
- National Security (21)
- Neutron Science (23)
- Quantum information Science (3)
- Sensors and Controls (1)
- Supercomputing (58)
- Transportation Systems (2)
News Type
News Topics
- (-) Biomedical (2)
- 3-D Printing/Advanced Manufacturing (4)
- Advanced Reactors (11)
- Bioenergy (1)
- Computer Science (2)
- Coronavirus (1)
- Cybersecurity (1)
- Decarbonization (1)
- Environment (1)
- Fusion (8)
- Isotopes (5)
- Materials Science (3)
- Molten Salt (4)
- Neutron Science (5)
- Nuclear Energy (36)
- Physics (2)
- Space Exploration (5)
- Sustainable Energy (1)
- Transformational Challenge Reactor (3)
Media Contacts
Oak Ridge National Laboratory researchers have discovered a better way to separate actinium-227, a rare isotope essential for an FDA-approved cancer treatment.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.